Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 258

Sort by

Sort Order Select

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study

Blood (2024) 144 (Supplement 1): 1473.

https://doi.org/10.1182/blood-2024-205776

Published: 2024

Journal Articles

A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience

Blood (2024) 144 (Supplement 1): 1488.

https://doi.org/10.1182/blood-2024-206291

Published: 2024

Journal Articles

Genomic Landscape of Germline RUNX1 variants in Adult Myeloid Neoplasia According to Functional Impact

Christopher Haddad, Luca Guarnera, Yasuo Kubota, Carlos Bravo-Perez, Carmelo Gurnari, Olisaemeka Ogbue, Arda Durmaz, Serhan Unlu, Aashray Mandala, Mark Orland, Zachary Brady, Kartik Lakhotiya, Matteo D'Addona, Ishani Nautiyal, David S. Bosler, Hetty E. Carraway, Yogen Saunthararajah, Valeria Visconte, Jaroslaw Maciejewski

Blood (2024) 144 (Supplement 1): 1328.

https://doi.org/10.1182/blood-2024-210419

Published: 2024

Journal Articles

Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 4248.

https://doi.org/10.1182/blood-2024-205329

Published: 2024

Journal Articles

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update

Blood (2024) 144 (Supplement 1): 219.

https://doi.org/10.1182/blood-2024-200393

Published: 2024

Journal Articles

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Ted M. Getz, Tariq Kewan, Jan Philipp Bewersdorf, Jessica M. Stempel, Luca Lanino, Wei Wei, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Somedeb Ball, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Justin Grenet, Zhuoer Xie, Yazan F. Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vasiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Maximilian Stahl, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 3219.

https://doi.org/10.1182/blood-2024-202075

Published: 2024

Journal Articles

Unraveling Immunogenomic Features Germane to Pathobiology of Myelodysplastic Syndromes

Arda Durmaz, Zachary Brady, Kartik Lakhotiya, Benjamin Kroger, Hussein Awada, Yasuo Kubota, Jacky Chen, Colin Hercus, Sébastien Hergalant, Carlos Bravo-Perez, Maria Teresa Voso, Li Lily Wang, Jacob G. Scott, Hetty E. Carraway, Valeria Visconte, Stephen Chung, Simona Pagliuca, Jaroslaw Maciejewski, Carmelo Gurnari

Blood (2024) 144 (Supplement 1): 2224.

https://doi.org/10.1182/blood-2024-198530

Published: 2024

Journal Articles

Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience

Blood (2024) 144 (Supplement 1): 4249.

https://doi.org/10.1182/blood-2024-206218

Published: 2024

Journal Articles

The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience

Blood (2024) 144 (Supplement 1): 4297.

https://doi.org/10.1182/blood-2024-206289

Published: 2024

Journal Articles

Analysis of Factors Influencing Enrollment Success in Hematology Malignancy Cancer Clinical Trials (2008-2023)

Rupayan Kundu, Xiaoying Chen, Wei Wei, Debolina Pramanik, Yash Agarwal, Arjun Chatterjee, Akriti G. Jain, Abhay Singh, Aaron T. Gerds, Hetty E. Carraway, Moaath K. Mustafa Ali, John C. Molina, Sophia Balderman, Sudipto Mukherjee

Blood (2024) 144 (Supplement 1): 5059.

https://doi.org/10.1182/blood-2024-207446

Published: 2024

Journal Articles

Geno-Transcriptomic Topography of Clonal Drivers in Trisomy 8 Myeloid Malignancies

Hussein Awada, Carmelo Gurnari, Yasuo Kubota, Carlos Bravo-Perez, Luca Guarnera, Matteo D'Addona, Zachary Brady, Mark Orland, Serhan Unlu, Arda Durmaz, Hetty E. Carraway, Hassan Awada, Jaroslaw Maciejewski, Valeria Visconte

Blood (2024) 144 (Supplement 1): 2943.

https://doi.org/10.1182/blood-2024-209374

Published: 2024

Journal Articles

Impact of TP53 Mutation on Survival Outcomes in Acute Lymphoblastic Leukemia at a Tertiary Center

Meera Patel, Ahmed N Mohamed, Hadil Zureigat, Emily C. Zabor, Daniel P. Nurse, Yohana B. Bedelu, Mark Jinan Chen, Joy Nakitandwe, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Sudipto Mukherjee, Hetty E. Carraway, Anjali S. Advani, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 4221.

https://doi.org/10.1182/blood-2024-199333

Published: 2024

Journal Articles

Impact of P190 and P210 BCR::ABL1 Chimeric Protein on Outcomes of Acute Lymphoblastic Leukemia at a Tertiary Center

Ahmed N Mohamed, Meera Patel, Hadil Zureigat, Daniel P. Nurse, Sara F Haddad, Emily C. Zabor, Yohana B. Bedelu, Mark Jinan Chen, Joy Nakitandwe, John C. Molina, Sophia Balderman, Akriti G. Jain, Abhay Singh, Sudipto Mukherjee, Aaron T. Gerds, Hetty E. Carraway, Anjali S. Advani, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 5909.

https://doi.org/10.1182/blood-2024-202558

Published: 2024

Journal Articles

Impact of Non- ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia

Akriti G. Jain, Joy Nakitandwe, Krishna Desai, Genevieve M Crane, David S. Bosler, Jill O'Brien, Moaath K. Mustafa Ali, John C. Molina, Sophia Balderman, Anjali S. Advani, Hetty E. Carraway, Aaron T. Gerds, Abhay Singh, Matt Kalaycio, Sudipto Mukherjee

Blood (2024) 144 (Supplement 1): 3153.

https://doi.org/10.1182/blood-2024-209165

Published: 2024

Journal Articles

Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study

Blood (2024) 144 (Supplement 1): 1777.

https://doi.org/10.1182/blood-2024-212146

Published: 2024

Journal Articles

Outcomes of Second-Line Tyrosine Kinase Inhibitors after First-Line Imatinib in Chronic Myelogenous Leukemia: A Retrospective Cohort Study

Muaz Alsabbagh Alchirazi, Hadil Zureigat, Ahmed N Mohamed, Aastha Dhakal, Ali Mushtaq, Naveen Rehman, Bryan Berube, Sneha Govande, Emily C. Zabor, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Anjali S. Advani, Hetty E. Carraway, Matt Kalaycio, Sudipto Mukherjee, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 6597.

https://doi.org/10.1182/blood-2024-206448

Published: 2024

Journal Articles

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

Mikkael A. Sekeres, Hetty E. Carraway, Richard M Stone, Yazan F Madanat, Rami S. Komrokji, Sangeetha Venugopal, Namrata S. Chandhok, Terrence Bradley, Justin Taylor, Anastasia Santiago, Alessia Zoso, Justin M. Watts, Amy E. DeZern

Blood (2024) 144 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2024-203965

Published: 2024

Journal Articles

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Blood (2024) 144 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2024-206538

Published: 2024

Journal Articles

Evaluating Impact of Insertion Length on Clinical Outcomes in FLT3-ITD Mutated AML: A Single Center Retrospective Analysis

Blood (2024) 144 (Supplement 1): 6143.

https://doi.org/10.1182/blood-2024-209265

Published: 2024

NARROW

Risk prediction for clonal cytopenia: multicenter real-world evidence

Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study

A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience

Genomic Landscape of Germline RUNX1 variants in Adult Myeloid Neoplasia According to Functional Impact

Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Unraveling Immunogenomic Features Germane to Pathobiology of Myelodysplastic Syndromes

Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience

The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience

Analysis of Factors Influencing Enrollment Success in Hematology Malignancy Cancer Clinical Trials (2008-2023)

Geno-Transcriptomic Topography of Clonal Drivers in Trisomy 8 Myeloid Malignancies

Impact of TP53 Mutation on Survival Outcomes in Acute Lymphoblastic Leukemia at a Tertiary Center

Impact of P190 and P210 BCR::ABL1 Chimeric Protein on Outcomes of Acute Lymphoblastic Leukemia at a Tertiary Center

Impact of Non- ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia

Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study

Outcomes of Second-Line Tyrosine Kinase Inhibitors after First-Line Imatinib in Chronic Myelogenous Leukemia: A Retrospective Cohort Study

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Evaluating Impact of Insertion Length on Clinical Outcomes in FLT3-ITD Mutated AML: A Single Center Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only